A variety of recent evidence exists about the clinical implication of low level of Pregnancyassociated plasma protein A (PAPP-A) in pregnancy. This glycoprotein is a protease, which releases the Insulinlike growth factor from IGFBP 4. Its role is a trophoblastic invasion of decidua, stimulation of cell mitosis and differentiation. It has an immunosuppressive effect in the placenta, inhibition of coagulation and complex role for integration of all these processes in the placenta. Level of PAPP-A (under 0.4 MoM-Multiple of Medians) in firsttrimester screening in chromosomally and morphologically normal fetuses, could influence fetal weight, preeclampsia, premature birth and stillbirth. As a result of the complications mentioned above, there is implication on timing, mode of delivery and condition of the newborn.
Introduction
The measurement of Pregnancy-associated plasma protein A in the first trimester of pregnancy (PAPP-A), is a part of the combined screening in the first trimester for chromosomopathies, according to the recommendations of the Fetal Medicine Foundation (FMF) [1] , [2] . Since its discovery by Lin in 1974, till now, this glycoprotein remains a dilemma about the interpretation of its concentrations in placenta and blood in pregnant women during https://www.id-press.eu/mjms/index pregnancy, in the first trimester and use in everyday practice [3] . PAPP-A is a large glycoprotein in complex with eosinophilic pro-Major basic protein (pro-MBP) [4] . It is a highly potent protease for insulinlike growth factor binding protein 4 and 5 (IGFBP 4 and 5). The protein is a powerful inhibitor of IGF in vitro, suggesting that proteolysis acts like a positive regulator of the IGF-availability. PAPP-A in the serum of the pregnant woman has an IGF-dependent protease activity on IGFBP-4 [5] . This protease has an important role in the local proliferative answer, acting by accelerating the cell division. It increases the bioavailability of IGF, which in return mediates the trophoblastic invasion of decidua and modulates the transport of glucose and amino acids in the placenta [4] , [5] , [6] . Thus, low PAPP -A might be a cause for inappropriate placental perfusion affecting the fetal growth and leading to placental depended on adverse conditions in pregnancy [7] , [8] . PAPP-A is a placental product from syncytiotrophoblast and septal X cells, and its concentration is low in the first trimester. Insufficient syncytiotrophoblast development and function have an important role in the abnormal placental secretion of main placental proteins (beta HCG, PAPP-A, SP1 and HPL) [3] , [4] , [7] , [9] . The median value for PAPP-A increase from 0.4 MoM in a 10 th gestational week to approximately 0.7 MoM in the 13 th gestational week, so the PAPP-A increases as the pregnancy progresses till term [7] , [8] , [9] . Does low value of PAPP-A (< 0.4 MoM) could predict an adverse perinatal outcome that includes fetuses with intrauterine growth restriction (IUGR) resulting in SGA infant in most of the cases, preeclampsia and preterm birth is still unclear [10] , [11] , [12] , [13] , [14] , [15] .
The study aims to evaluate the influence of low PAPP-A, measured in the first trimester on the outcome of pregnancy, with accent disorders which are the result of placental insufficiency. Also, gestational week, mode of delivery and condition of newborn secondary underlying conditions will be evaluated.
Material and Methods
This study was submitted and approved by the Ethical Review Committee of the Medical Faculty in Skopje and is in adherence to the laws and regulations of the country in which the research was conducted. Written consent with patient permission was obtained from each patient. A prospective longitudinal study was conducted at the University Clinic of Gynecology and Obstetrics, Skopje. Analyses for PAPP -A were performed at the Biochemical, clinical laboratory. chromosomopathies were excluded at Cytogenetic laboratory. The pregnant women were followed up during the pregnancy and delivered 2017 and 2018. After First Trimester screening, if the risk was < 1:250, prenatal genetic testing to exclude chromosomopathies was offered. A total of 114 patients without chromosomopathies and congenital malformations enrolled in the study. Depend on the level of PAPP-A; there were 64 patients in the target group with values of PAPP-A below of 0.4 MoM and 50 patients in the control group with values of PAPP-A ≥ 0.4 MoM. The data for the patients was collected by a questionnaire that included demographic information, information about the current pregnancy, personal and obstetric history. In both groups, the presence of obstetrical complications such as preeclampsia, small for gestational age, premature deliveries, fetal distress, mode of delivery and indications for caesarean section were evaluated. The definition of hypertensive disorders, small for gestational age and preterm delivery was by relevant obstetric guidelines. The newborn's condition at delivery was evaluated. 
Results
A total of 114 patients were enrolled. The patients were divided into two groups: target group-64 patients and control-50 patients.
Maternal age -the average age in the target group was 28.8 ± 4.8 years and the control 30.6 ± 5.3 years, p = 0.057 (Table 1 ). Gestational age of delivery was similar between two groups, p = 0.87 (Table 2 ). The mode of deliveryvaginal vs caesarean section wasn't significantly different between the groups (p = 0.79). Delivery by caesarean section occurred in 29.7% target group vs 32% of the control group (Table 3) . We didn't find a difference between delivery by elective vs urgent caesarean section, (p = 0.51).
The results show a significant difference in complications in pregnancy before delivery, among the groups (p = 0.023) ( Table 4 ). Distribution of complications is present in Table 5 . The most frequent complications were premature birth and SGA newborn in the target group. There are a discrepancy in the total number (n = 45) and patients with (noted as main) complications (n = 38) because more than one complication is present in the same patient. The frequency of SGA newborn has significant statistical difference p = 0.023 (Table 6 ). In the target group, the duration of pregnancy till 37 g. w. or less was significantly more frequent than in control-32.8% (21) vs.16% (8), p = 0.04 (Table  7 ). 
Outcome of newborn
Average birth weight was (in grams) 3028.9 ± 743.4 vs. 3175.4 ± 677.9. p = 0.13 Very similar results were for birth height (in cm) 48.94 ± 3.1 vs. 49.36 ± 3.5, p = 0.21.
Viability of newborn
The value of Apgar score in the first and fifth minute, didn't show statistical significance (p = 0.43, p = 0.19) respectively, although they were lower in the target group at the fifth minute (Table 8 ). 
Discussion
Level of PAPP-A (under 0.4 MoM) in firsttrimester screening in chromosomally and morphologically healthy fetuses, could contribute to the placental mediated complication, such as preeclampsia, premature birth, SGA, stillbirth, miscarriages [15] , [16] . This implies on time and mode of delivery and newborn outcome.
In the study, there were no significant differences in maternal age. The total premature deliveries were due to uterine contractions and iatrogenic termination because of complications in pregnancy. The frequency of pregnancy up to 37 g.w. in target group was higher with statistical significance (p = 0.04) [15] , [17] . We didn't find a difference for preeclampsia compare to other studies [16] , [17] . https://www.id-press.eu/mjms/index There are studies for positive association between complications and low level of PAPP-A under 0.3 MoM [12] , [13] , [18] , [19] .
In our study urgent cesarean sections rate is almost 20% and is similar in both groups. Other studies present higher once in target group-30% [14] .
Preeclampsia was present around 10% in the target group, similar to unselected pregnant women (6-8%) . Almost 17% of a newborn in the target group were small for gestational age below the 10 th percentile, higher than in Thompson study-7.44% [20] .
Some studies show a significant difference in an adverse outcome in a group with PAPP-A below 0.4 MoM, probably because of different statistical power [21] , [22] .
There are a lot of studies with a different outcome. They included patients with different characteristics (race origin, body weight, previous poor obstetric history). Also, the presence of underlying disorders such as hypertension, diabetes, hypothyreosis, autoimmune disease etc. was included. In our study, the patients didn't have these conditions as they were exclusion criteria in the study. The number of patients enrolled in the studies is different; from national level study to trial study. Our study was with a relatively lower number of patients according to other studies. Better predictive results have studies which involve other tests (doppler of uterine arteries and fetal dopplers, different biochemical tests) [21] , [23] , [24] .
In conclusion, there is a difference in unfavourable outcome in the cases with PAPP-A under 0.4 MoM, particular in the group of patients with premature birth, and SGA as a result of placental insufficiency. These factors lead to fetal distress or compromised fetal oxygenation. The patients delivered with cesarean section were with the main contributing factor-preterm fetus. Compare with the control group, these complications in pregnancy were rare. In the control group, the main indications was previous one or more cesarean section, disproportion, transverse lie or breech presentation of the fetus. Birth weight, average gestational age and Apgar score were similar in target and control group. The detection rates could be improved with appropriate intervention before complications arise.
In term of fact, there are national recommendations for follow up of patients with low values of PAPP-A, we should attempt other countries. The main aim will be improving the perinatal outcome for mothers and the newborns. It is necessary to assess the cost-benefit if recommendations are going to be implemented in our circumstances.
